Modulation of behavior by the histaminergic system: Lessons from HDC-, H3R- and H4R-deficient mice

Neuroscience and Biobehavioral Reviews

Volumn 47, Issue , 2014, Pages 101-121

  Schneider, Erich H ^a   Neumann, Detlef ^a   Seifert, Roland ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Behavior; Brain; Food intake; Histamine receptor; Histidine decarboxylase; Knockout mouse; Learning; Memory; Pain; Seizures; Sleep

Indexed keywords

ALCOHOL; HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; HISTIDINE DECARBOXYLASE; G PROTEIN COUPLED RECEPTOR; HISTAMINE RECEPTOR; HRH4 PROTEIN, MOUSE;

ADDICTION; ALCOHOLISM; ALZHEIMER DISEASE; ANXIETY; ANXIETY DISORDER; AROUSAL; BEHAVIOR; BRAIN NERVE CELL; BRAIN REGION; CIRCADIAN RHYTHM; COGNITION; DOPAMINERGIC SYSTEM; FOOD INTAKE; GILLES DE LA TOURETTE SYNDROME; HISTAMINE RELEASE; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; LEARNING; LOCOMOTION; MEMORY; MOTOR COORDINATION; MOUSE; MULTIINFARCT DEMENTIA; NARCOLEPSY; NOCICEPTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PRURITUS; REVIEW; SEIZURE; SLEEP WAKING CYCLE; ANIMAL; BRAIN; GENETICS; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; PHYSIOLOGY;

ANIMALS; BRAIN; CIRCADIAN RHYTHM; HISTAMINE; HISTIDINE DECARBOXYLASE; MICE; MICE, KNOCKOUT; NEURONS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; RECEPTORS, HISTAMINE H3;

EID: 84906688857     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.07.020     Document Type: Review

References (178)

1. Abe H., Honma S., Ohtsu H., Honma K. Circadian rhythms in behavior and clock gene expressions in the brain of mice lacking histidine decarboxylase. Brain Res. Mol. Brain Res. 2004, 124:178-187.
2. -/-) mice. Brain Res. 2006, 1071:113-123.
3. -/-) mice. Behav. Brain Res. 2006, 168:92-99.
4. Acevedo S.F., Raber J. Histamine-dependent behavioral response to methamphetamine in 12-month-old male mice. Brain Res. 2011, 1393:23-30.
5. Agúndez J.A.G., Luengo A., Herráez O., Martínez C., Alonso-Navarro H., Jiménez-Jiménez F.J., Elena G.-M. Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson's disease. Neuromol. Med. 2008, 10:10-16.
6. Anaclet C., Parmentier R., Ouk K., Guidon G., Buda C., Sastre J.P., Akaoka H., Sergeeva O.A., Yanagisawa M., Ohtsu H., Franco P., Haas H.L., Lin J.S. Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J. Neurosci. 2009, 29:14423-14438.
7. 3 receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol. Dis. 2001, 8:707-716.
8. 4R receptors with 34 antidepressants and antipsychotics. Naunyn. Schmiedebergs Arch. Pharmacol. 2012, 385:145-170.
9. 2-receptor knockout. J. Gastroenterol. 2007, 42:711-718.
10. 3 receptor. Trends Pharmacol. Sci. 2007, 28:350-357.
11. 3 receptor antagonist, GSK239512, in vivo in human brain, determined using PET. Br. J. Pharmacol. 2014, 171:1241-1249.
12. 3 receptor antagonist ST1283 on voluntary alcohol consumption and ethanol-induced place preference in mice. Psychopharmacology (Berl.) 2013, 228:85-95.
13. 3 receptor antagonist ST-1283. Drug Des. Dev. Ther. 2014, 8:627-637.
14. 3 antagonist. Br. J. Pharmacol. 2004, 143:649-661.
15. Bekkers J.M. Enhancement by histamine of NMDA-mediated synaptic transmission in the hippocampus. Science 1993, 261:104-106.
16. 4-receptor lack specificity. Naunyn. Schmiedebergs Arch. Pharmacol. 2012, 385:125-135.
17. 1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br. J. Pharmacol. 2004, 142:374-380.
18. Bodei S., Arrighi N., Spano P., Sigala S. Should we be cautious on the use of commercially available antibodies to dopamine receptors?. Naunyn. Schmiedebergs Arch. Pharmacol. 2009, 379:413-415.
19. Bongers G., de Esch I., Leurs R. Molecular pharmacology of the four histamine receptors. Adv. Exp. Med. Biol. 2010, 709:11-19.
20. 3 isoform confers pharmacological differences and constitutive activity. J. Pharmacol. Exp. Ther. 2007, 323:888-898.
21. -/- mice. Neuropsychopharmacology 2004, 29:441-449.
22. 3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology (Berl.) 2009, 202:673-687.
23. 3-receptor inverse agonist pitolisant improves fear memory in mice. Behav. Brain Res. 2013, 243:199-204.
24. Brabant C., Quertemont E., Anaclet C., Lin J.S., Ohtsu H., Tirelli E. The psychostimulant and rewarding effects of cocaine in histidine decarboxylase knockout mice do not support the hypothesis of an inhibitory function of histamine on reward. Psychopharmacology (Berl.) 2007, 190:251-263.
25. 4 receptors. J. Physiol. 2007, 583:731-742.
26. Cacabelos R., Yamatodani A., Niigawa H., Hariguchi S., Tada K., Nishimura T., Wada H., Brandeis L., Pearson J. Brain histamine in Alzheimer's disease. Methods Find. Exp. Clin. Pharmacol. 1989, 11:353-360.
27. 3 receptors in the rat basolateral amygdala improves expression of fear memory and enhances acetylcholine release. Eur. J. Neurosci. 2002, 16:521-528.
28. 3 receptors inhibits mechanical nociception. Eur. J. Pharmacol. 2003, 470:139-147.
29. Castellan Baldan L., Williams K.A., Gallezot J.D., Pogorelov V., Rapanelli M., Crowley M., Anderson G.M., Loring E., Gorczyca R., Billingslea E., Wasylink S., Panza K.E., Ercan-Sencicek A.G., Krusong K., Leventhal B.L., Ohtsu H., Bloch M.H., Hughes Z.A., Krystal J.H., Mayes L., de Araujo I., Ding Y.S., State M.W., Pittenger C. Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. Neuron 2014, 81:77-90. (Erratum, 2014: Neuron 82, 1186-1187).
30. v mice. Brain Res. 2003, 968:162-166.
31. Chepkova A., Yanovsky E., Parmentier R., Ohtsu H., Haas H.L., Lin J.S., Sergeeva O.A. Histamine receptor expression, hippocampal plasticity and ammonia in histidine decarboxylase knockout mice. Cell. Mol. Neurobiol. 2012, 32:17-25.
32. Chung K., Wallace J., Kim S.Y., Kalyanasundaram S., Andalman A.S., Davidson T.J., Mirzabekov J.J., Zalocusky K.A., Mattis J., Denisin A.K., Pak S., Bernstein H., Ramakrishnan C., Grosenick L., Gradinaru V., Deisseroth K. Structural and molecular interrogation of intact biological systems. Nature 2013, 497:332-337.
33. 3 receptors in the feeding-related hypothalamic ventromedial nucleus. Br. J. Pharmacol. 2012, 167:1099-1110.
34. 4 receptor is functionally expressed on neurons in the mammalian CNS. Br. J. Pharmacol. 2009, 157:55-63.
35. Crabbe J.C., Wahlsten D., Dudek B.C. Genetics of mouse behavior: interactions with laboratory environment. Science 1999, 284:1670-1672.
36. 2 receptors. Neurosci. Res. 2007, 57:306-313.
37. Dauvilliers Y., Bassetti C., Lammers G.J., Arnulf I., Mayer G., Rodenbeck A., Lehert P., Ding C.L., Lecomte J.M., Schwartz J.C. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013, 12:1068-1075.
38. De la Herran-Arita A.K., Garcia-Garcia F. Narcolepsy as an immune-mediated disease. Sleep Disord. 2014, 2014:792687.
39. Dere E., De Souza-Silva M.A., Spieler R.E., Lin J.S., Ohtsu H., Haas H.L., Huston J.P. Changes in motoric, exploratory and emotional behaviours and neuronal acetylcholine content and 5-HT turnover in histidine decarboxylase-KO mice. Eur. J. Neurosci. 2004, 20:1051-1058.
40. Dere E., De Souza-Silva M.A., Topic B., Spieler R.E., Haas H.L., Huston J.P. Histidine-decarboxylase knockout mice show deficient nonreinforced episodic object memory, improved negatively reinforced water-maze performance, and increased neo- and ventro-striatal dopamine turnover. Learn. Mem. 2003, 10:510-519.
41. 4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability. Br. J. Pharmacol. 2012, 167:905-916.
42. 4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J. Allergy Clin. Immunol. 2007, 119:176-183.
43. 3 receptor. Trends Neurosci. 2014, 37:191-199.
44. Ercan-Sencicek A.G., Stillman A.A., Ghosh A.K., Bilguvar K., O'Roak B.J., Mason C.E., Abbott T., Gupta A., King R.A., Pauls D.L., Tischfield J.A., Heiman G.A., Singer H.S., Gilbert D.L., Hoekstra P.J., Morgan T.M., Loring E., Yasuno K., Fernandez T., Sanders S., Louvi A., Cho J.H., Mane S., Colangelo C.M., Biederer T., Lifton R.P., Gunel M., State M.W. l-Histidine decarboxylase and Tourette's syndrome. N. Engl. J. Med. 2010, 362:1901-1908.
45. Fernandez T.V., Sanders S.J., Yurkiewicz I.R., Ercan-Sencicek A.G., Kim Y.S., Fishman D.O., Raubeson M.J., Song Y., Yasuno K., Ho W.S., Bilguvar K., Glessner J., Chu S.H., Leckman J.F., King R.A., Gilbert D.L., Heiman G.A., Tischfield J.A., Hoekstra P.J., Devlin B., Hakonarson H., Mane S.M., Gunel M., State M.W. Rare copy number variants in Tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. Biol. Psychiatry 2012, 71:392-402.
46. 2 receptors and the implications for striatal function. Neuropharmacology 2008, 55:190-197.
47. 2 receptor expression in histidine decarboxylase knockout mice. FEBS Lett. 2001, 508:245-248.
48. Fülöp A.K., Földes A., Buzás E., Hegyi K., Miklós I.H., Romics L., Kleiber M., Nagy A., Falus A., Kovács K.J. Hyperleptinemia, visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene. Endocrinology 2003, 144:4306-4314.
49. 2 receptor-null mice. Eur. J. Pharmacol. 2003, 468:47-58.
50. 4 receptor modulation in the central nervous system. Neuropharmacology 2013, 71:141-147.
51. 3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl.) 2011, 214:829-841.
52. Gastinger M.J., Barber A.J., Vardi N., Marshak D.W. Histamine receptors in mammalian retinas. J. Comp. Neurol. 2006, 495:658-667.
53. 3 receptor agonists reduce l-Dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 2006, 21:839-846.
54. 3-receptor knock-out mice. Neuropsychopharmacology 2013, 38:1015-1031.
55. Gong Y.X., Shou W.T., Feng B., Zhang W.P., Wang H.J., Ohtsu H., Chen Z. Ameliorating effect of histamine on impairment of cued fear extinction induced by morphine withdrawal in histidine decarboxylase gene knockout mice. Acta Pharmacol. Sin. 2010, 31:1431-1437.
56. Gong Y.X., Zhang W.P., Shou W.T., Zhong K., Chen Z. Morphine induces conditioned place preference behavior in histidine decarboxylase knockout mice. Neurosci. Lett. 2010, 468:115-119.
57. 3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. Eur. J. Neurosci. 1999, 11:449-456.
58. 3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Curr. Alzheimer Res. 2014, 11:47-58.
59. Gutzmer R., Werfel T., Bäumer W., Kietzmann M., Chazot P.L., Leurs R. Well characterized antihistamine 4 receptor antibodies contribute to current knowledge of the expression and biology of the human and murine histamine 4 receptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 2012, 385:853-854.
60. Haas H.L., Sergeeva O.A., Selbach O. Histamine in the nervous system. Physiol. Rev. 2008, 88:1183-1241.
61. 3 receptor antagonist. Eur. J. Pharmacol. 2004, 487:183-197.
62. 3 receptor antagonists/inverse agonists. Expert Opin. Investig. Drugs 2005, 14:223-241.
63. Hill S.J., Ganellin C.R., Timmerman H., Schwartz J.C., Shankley N.P., Young J.M., Schunack W., Levi R., Haas H.L. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev. 1997, 49:253-278.
64. 1 receptor-deficient mice. Epilepsia 2004, 45:309-313.
65. 4 receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. Exp. Ther. 2003, 305:1212-1221.
66. 4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacol. Biochem. Behav. 2010, 95:41-50.
67. Huston J.P., Wagner U., Hasenohrl R.U. The tuberomammillary nucleus projections in the control of learning, memory and reinforcement processes: evidence for an inhibitory role. Behav. Brain Res. 1997, 83:97-105.
68. 3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin. Neuropharmacol. 2012, 35:55-60.
69. 1 receptors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13316-13320.
70. Ishiguro T., Iwase M., Kanamaru M., Izumizaki M., Ohshima Y., Homma I. Contribution of histamine type-1 receptor to metabolic and behavioral control of ventilation. J. Physiol. Sci. 2006, 56:287-295.
71. 3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Biol. Psychiatry 1999, 45:475-481.
72. Iwabuchi K., Kubota Y., Ito C., Watanabe T., Watanabe T., Yanai K. Methamphetamine and brain histamine: a study using histamine-related gene knockout mice. Ann. N. Y. Acad. Sci. 2004, 1025:129-134.
73. John J., Thannickal T.C., McGregor R., Ramanathan L., Ohtsu H., Nishino S., Sakai N., Yamanaka A., Stone C., Cornford M., Siegel J.M. Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann. Neurol. 2013, 74:786-793.
74. Jørgensen E.A., Vogelsang T.W., Knigge U., Watanabe T., Warberg J., Kjaer A. Increased susceptibility to diet-induced obesity in histamine-deficient mice. Neuroendocrinology 2006, 83:289-294.
75. Jutel M., Akdis M., Akdis C.A. Histamine, histamine receptors and their role in immune pathology. Clin. Exp. Allergy 2009, 39:1786-1800.
76. Kajihara Y., Murakami M., Imagawa T., Otsuguro K., Ito S., Ohta T. Histamine potentiates acid-induced responses mediating transient receptor potential V1 in mouse primary sensory neurons. Neuroscience 2010, 166:292-304.
77. Karagiannidis I., Dehning S., Sandor P., Tarnok Z., Rizzo R., Wolanczyk T., Madruga-Garrido M., Hebebrand J., Nothen M.M., Lehmkuhl G., Farkas L., Nagy P., Szymanska U., Anastasiou Z., Stathias V., Androutsos C., Tsironi V., Koumoula A., Barta C., Zill P., Mir P., Müller N., Barr C., Paschou P. Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. J. Med. Genet. 2013, 50:760-764.
78. Keeling B.H., Vilariño-Güell C., Soto-Ortolaza A.I., Ross O.A., Uitti R.J., Rajput A., Wszolek Z.K., Farrer M.J. Histamine N-methyltransferase Thr105Ile is not associated with Parkinson's disease or essential tremor. Parkinsonism Relat. Disord. 2010, 16:112-114.
79. 2 receptor-deficient mice. J. Clin. Invest. 2000, 105:1741-1749.
80. Krusong K., Ercan-Sencicek A.G., Xu M., Ohtsu H., Anderson G.M., State M.W., Pittenger C. High levels of histidine decarboxylase in the striatum of mice and rats. Neurosci. Lett. 2011, 495:110-114.
81. Kubota Y., Ito C., Sakurai E., Sakurai E., Watanabe T., Ohtsu H. Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice. J. Neurochem. 2002, 83:837-845.
82. 1 receptors mediate l-histidine-induced anxiety in elevated plus-maze test in mice. Behav. Pharmacol. 2007, 18:213-217.
83. Lei J., Deng X., Zhang J., Su L., Xu H., Liang H., Huang X., Song Z., Deng H. Mutation screening of the HDC gene in Chinese Han patients with Tourette syndrome. Am. J. Med. Genet. B 2011, 159B:72-76.
84. 4R antibody. Inflamm. Res. 2010, 59(Suppl. 2):S197-S198.
85. 3 receptor drugs. Nat. Rev. Drug Discov. 2005, 4:107-120.
86. Liu L., Zhang S., Zhu Y., Fu Q., Zhu Y., Gong Y., Ohtsu H., Luo J., Wei E., Chen Z. Improved learning and memory of contextual fear conditioning and hippocampal CA1 long-term potentiation in histidine decarboxylase knock-out mice. Hippocampus 2007, 17:634-641.
87. Llorca P.-M., Spadone M., Sol O., Danniau A., Bougerol T., Corruble E., Faruch M., Macher J.-P., Sermet E., Servant D. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J. Clin. Psychiatry 2002, 63:1020-1027.
88. 3 receptor sites in autopsied brain tissue from cirrhotic patients who died in hepatic coma. J. Hepatol. 2003, 39:522-527.
89. 3 receptors - general characterization and their function in the cardiovascular system. J. Physiol. Pharmacol. 1998, 49:191-211.
90. 3 receptor antagonist on hypothalamic neural activity, food intake and body weight. Int. J. Obes. (Lond.) 2005, 29:1402-1412.
91. 2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Synapse 1993, 15:209-220.
92. 1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004, 53:2250-2260.
93. Mazurkiewicz-Kwilecki I.M., Nsonwah S. Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can. J. Physiol. Pharmacol. 1989, 67:75-78.
94. 3 receptors in Alzheimer's disease brain and amyloid over-expressing TASTPM mice. Br. J. Pharmacol. 2009, 157:130-138.
95. 1 receptor in pain perception: a study of the receptor gene knockout mice. Eur. J. Pharmacol. 2000, 391:81-89.
96. 2 receptor gene knockout mice. Neuropharmacology 2006, 51:612-622.
97. 3 receptor gene knockout mice. Neuropharmacology 2009, 57:409-414.
98. 3 receptor-mediated increase in exploratory locomotor activity and anxiety-like behaviours in mice. Neuropharmacology 2014, 81:188-194.
99. Morimoto T., Yamamoto Y., Mobarakeh J.I., Yanai K., Watanabe T., Watanabe T., Yamatodani A. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol. Behav. 1999, 67:679-683.
100. 3 receptors regulates histamine neurons in brain. Nature 2000, 408:860-864.
101. Motawaj M., Burban A., Davenas E., Arrang J.-M. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease. J. Pharmacol. Exp. Ther. 2011, 336:479-487.
102. Nakaya M., Takeuchi N., Kondo K. Immunohistochemical localization of histamine receptor subtypes in human inferior turbinates. Ann. Otol. Rhinol. Laryngol. 2004, 113:552-557.
103. 3-histamine receptors increases the release of prolactin in male rats. Neuroendocrinology 1993, 57:654-657.
104. 4 receptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 2012, 385:855-860.
105. Neumann D., Schneider E.H., Seifert R. Analysis of histamine receptor knock-out mice in models of inflammation. J. Pharmacol. Exp. Ther. 2014, 348:2-11.
106. Nowak P., Noras Ł., Jochem J., Szkilnik R., Brus H., Körossy E., Drab J., Kostrzewa R.M., Brus R. Histaminergic activity in a rodent model of Parkinson's disease. Neurotox. Res. 2009, 15:246-251.
107. 3 receptor ligands modulate l-dopa-evoked behavioral responses and l-dopa derived extracellular dopamine in dopamine-denervated rat striatum. Neurotox. Res. 2008, 13:231-240.
108. 3 receptor-dependent mechanisms regulate ethanol stimulation and conditioned place preference in mice. Psychopharmacology (Berl.) 2010, 208:75-86.
109. 3 receptor in alcohol consumption and alcohol reward in mice. Neuropsychopharmacology 2011, 36:2030-2040.
110. 3 receptor ligands on the rewarding, stimulant and motor-impairing effects of ethanol in DBA/2J mice. Neuropharmacology 2011, 60:1193-1199.
111. 2 receptor knock-out mice. Brain Res. Bull. 2009, 78:189-194.
112. Ohtsu H., Tanaka S., Terui T., Hori Y., Makabe-Kobayashi Y., Pejler G., Tchougounova E., Hellman L., Gertsenstein M., Hirasawa N., Sakurai E., Buzas E., Kovacs P., Csaba G., Kittel A., Okada M., Hara M., Mar L., Numayama-Tsuruta K., Ishigaki-Suzuki S., Ohuchi K., Ichikawa A., Falus A., Watanabe T., Nagy A. Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett. 2001, 502:53-56.
113. 3-receptor knockout mice. J. Pharmacol. Sci. 2009, 111:167-174.
114. Oroszi G., Enoch M.-A., Chun J., Virkkunen M., Goldman D. Thr105Ile, a functional polymorphism of histamine N-methyltransferase, is associated with alcoholism in two independent populations. Alcohol. Clin. Exp. Res. 2005, 29:303-309.
115. Palada V., Terzić J., Mazzulli J., Bwala G., Hagenah J., Peterlin B., Hung A.Y., Klein C., Dimitri K. Histamine N-methyltransferase Thr105Ile polymorphism is associated with Parkinson's disease. Neurobiol. Aging 2012, 33. 836.e1-836.e3.
116. Palkovits M., Deli M.A., Gallatz K., Tóth Z.E., Buzás E., Falus A. Highly activated c-fos expression in specific brain regions (ependyma, circumventricular organs, choroid plexus) of histidine decarboxylase deficient mice in response to formalin-induced acute pain. Neuropharmacology 2007, 53:101-112.
117. 3 receptor in alcohol-related behaviors. J. Pharmacol. Exp. Ther. 2011, 336:9-16.
118. Panula P., Nuutinen S. The histaminergic network in the brain: basic organization and role in disease. Nat. Rev. Neurosci. 2013, 14:472-487.
119. Panula P., Rinne J., Kuokkanen K., Eriksson K.S., Sallmen T., Kalimo H., Relja M. Neuronal histamine deficit in Alzheimer's disease. Neuroscience 1998, 82:993-997.
120. Par G., Szekeres-Bartho J., Buzas E., Pap E., Falus A. Impaired reproduction of histamine deficient (histidine-decarboxylase knockout) mice is caused predominantly by a decreased male mating behavior. Am. J. Reprod. Immunol. 2003, 50:152-158.
121. Parmentier R., Ohtsu H., Djebbara-Hannas Z., Valatx J.L., Watanabe T., Lin J.S. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J. Neurosci. 2002, 22:7695-7711.
122. 3 receptor-mediated impairment of contextual fear conditioning and in-vivo inhibition of cholinergic transmission in the rat basolateral amygdala. Eur. J. Neurosci. 2001, 14:1522-1532.
123. 3 receptor ligands in experimental models of anxiety and depression. Psychopharmacology (Berl.) 1999, 142:215-220.
124. Pradidarcheep W., Stallen J., Labruyere W.T., Dabhoiwala N.F., Michel M.C., Lamers W.H. Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn. Schmiedebergs Arch. Pharmacol. 2009, 379:397-402.
125. Rinne J.O., Anichtchik O.V., Eriksson K.S., Kaslin J., Tuomisto L., Kalimo H., Röyttä M., Panula P. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. J. Neurochem. 2002, 81:954-960.
126. -/- mice. Eur. J. Neurosci. 2004, 19:1992-1996.
127. 4 receptors are involved in pruritus. Neuroscience 2011, 190:89-102.
128. 2 receptors in rat brain. Neuroreport 1994, 5:621-624.
129. Sakai K., Takahashi K., Anaclet C., Lin J.S. Sleep-waking discharge of ventral tuberomammillary neurons in wild-type and histidine decarboxylase knock-out mice. Front. Behav. Neurosci. 2010, 4:53.
130. 1 receptor-induced cAMP accumulation in rat striatal slices. Neurosci. Lett. 2004, 364:179-184.
131. 3 receptor coupled to defined Gi/Go protein heterotrimers. J. Pharmacol. Exp. Ther. 2010, 332:996-1005.
132. 3 receptor function by monovalent ions. Neurosci. Lett. 2010, 472:114-118.
133. 3-receptors. Biochem. Pharmacol. 2010, 80:1437-1449.
134. 2R-deficient mice. Neurosci. Biobehav. Rev. 2014, 42:252-266.
135. Schwartz J.C., Arrang J.M., Garbarg M., Pollard H., Ruat M. Histaminergic transmission in the mammalian brain. Physiol. Rev. 1991, 71:1-51.
136. Seifert R., Strasser A., Schneider E.H., Neumann D., Dove S., Buschauer A. Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol. Sci. 2013, 34:33-58.
137. Seifert R., Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn. Schmiedebergs Arch. Pharmacol. 2002, 366:381-416.
138. Seike M., Ikeda M., Kodama H., Terui T., Ohtsu H. Inhibition of scratching behaviour caused by contact dermatitis in histidine decarboxylase gene knockout mice. Exp. Dermatol. 2005, 14:169-175.
139. Shan L., Bossers K., Luchetti S., Balesar R., Lethbridge N., Chazot P.L., Bao A.-M., Swaab D.F. Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study. Neurobiol. Aging 2012, 33. 1488.e1-1488.e13.
140. Shan L., Bossers K., Unmehopa U., Bao A.M., Swaab D.F. Alterations in the histaminergic system in Alzheimer's disease: a postmortem study. Neurobiol. Aging 2012, 33:2585-2598.
141. Shan L., Hofman M.A., van Wamelen D.J., Van Someren E.J., Bao A.M., Swaab Dick F. Diurnal fluctuation in histidine decarboxylase expression, the rate limiting enzyme for histamine production, and its disorder in neurodegenerative diseases. Sleep 2012, 35:713-715.
142. Shan L., Liu C.Q., Balesar R., Hofman M.A., Bao A.M., Swaab D.F. Neuronal histamine production remains unaltered in Parkinson's disease despite the accumulation of Lewy bodies and Lewy neurites in the tuberomamillary nucleus. Neurobiol. Aging 2012, 33:1343-1344.
143. Shan L., Swaab D.F., Bao A.M. Neuronal histaminergic system in aging and age-related neurodegenerative disorders. Exp. Gerontol. 2013, 48:603-607.
144. 3 receptors in ischemic vascular and mixed dementias. J. Neurol. Sci. 2012, 315:110-114.
145. 2 receptors. Conference of the Society for Neuroscience 2001, Abstract 745.15.
146. Shin J.M., Vagin O., Munson K., Kidd M., Modlin I.M., Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell. Mol. Life Sci. 2008, 65:264-281.
147. 3R activation by thioperamide does not affect energy balance. Pharmacol. Biochem. Behav. 2004, 78:275-283.
148. 3 receptor function and ligands: recent developments. Mini Rev. Med. Chem. 2013, 13:47-57.
149. 4 receptors in mechanical hyperalgesia following peripheral nerve injury. Neuroimmunomodulation 2007, 14:317-325.
150. Söderpalm B., Löf E., Ericson M. Mechanistic studies of ethanol's interaction with the mesolimbic dopamine reward system. Pharmacopsychiatry 2009, 42(Suppl. 1):S87-S94.
151. 4 receptors in the central nervous system of human and rat. Brain Res. 2009, 1250:41-48.
152. Strasser A., Wittmann H.J., Buschauer A., Schneider E.H., Seifert R. Species-dependent activities of G-protein-coupled receptor ligands: lessons from histamine receptor orthologs. Trends Pharmacol. Sci. 2013, 34:13-32.
153. 3 receptors results in changes in brain histamine tone leading to an obese phenotype. J. Clin. Invest. 2002, 110:1791-1799.
154. Takino N., Sakurai E., Kuramasu A., Okamura N., Yanai K. Roles of the histaminergic neurotransmission on methamphetamine-induced locomotor sensitization and reward: a study of receptors gene knockout mice. Int. Rev. Neurobiol. 2009, 85:109-116.
155. 3 receptors by thioperamide and (R)-alpha-methylhistamine measured using histamine turnover and an ex vivo labeling technique. Biochem. Pharmacol. 1992, 44:1261-1267.
156. 3 receptors. Mol. Pharmacol. 2002, 62:389-397.
157. Valko P.O., Gavrilov Y.V., Yamamoto M., Reddy H., Haybaeck J., Mignot E., Baumann C.R., Scammell T.E. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann. Neurol. 2013, 74:794-804.
158. 4 receptors. Mol. Pharmacol. 2006, 70:604-615.
159. van Wamelen D.J., Shan L., Aziz N.A., Anink J.J., Bao A.-M., Roos R.A.C., Swaab D.F. Functional increase of brain histaminergic signaling in Huntington's disease. Brain Pathol. 2011, 21:419-427.
160. Wahlsten D., Metten P., Phillips T.J., Boehm S.L., Burkhart-Kasch S., Dorow J., Doerksen S., Downing C., Fogarty J., Rodd-Henricks K., Hen R., McKinnon C.S., Merrill C.M., Nolte C., Schalomon M., Schlumbohm J.P., Sibert J.R., Wenger C.D., Dudek B.C., Crabbe J.C. Different data from different labs: lessons from studies of gene-environment interaction. J. Neurobiol. 2003, 54:283-311.
161. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
162. Walter M., Stark H. Histamine receptor subtypes: a century of rational drug design. Front. Biosci. (Schol. Ed.) 2012, 4:461-488.
163. Wang K.-Y., Tanimoto A., Yamada S., Guo X., Ding Y., Watanabe T., Watanabe T., Kohno K., Hirano K.-I., Tsukada H., Sasaguri Y. Histamine regulation in glucose and lipid metabolism via histamine receptors. Model for nonalcoholic steatohepatitis in mice. Am. J. Pathol. 2010, 177:713-723.
164. 4 receptor polymorphism: a potential predictor of risperidone efficacy. J. Clin. Psychopharmacol. 2013, 33:221-225.
165. Whitehouse P.J., Trifiletti R.R., Jones B.E., Folstein S., Price D.L., Snyder S.H., Kuhar M.J. Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Ann. Neurol. 1985, 18:202-210.
166. 3-receptor agonist, in rats. J. Pharm. Pharmacol. 1994, 46:371-374.
167. 1 receptors. Neuroscience 1998, 87:479-487.
168. Yanovsky Y., Zigman J.M., Kernder A., Bein A., Sakata I., Osborne-Lawrence S., Haas H.L., Sergeeva O.A. Proton- and ammonium-sensing by histaminergic neurons controlling wakefulness. Front. Syst. Neurosci. 2012, 6. article 23.
169. 3 receptor agonists in animal models of anxiety: a comparative study with antidepressants and benzodiazepine anxiolytic. Psychopharmacology (Berl.) 2009, 205:177-187.
170. 1 receptors: a study in histidine decarboxylase gene knockout mice. Eur. J. Pharmacol. 2005, 522:55-62.
171. Yoshikawa T., Naganuma F., Iida T., Nakamura T., Harada R., Mohsen A.S., Kasajima A., Sasano H., Yanai K. Molecular mechanism of histamine clearance by primary human astrocytes. Glia 2013, 61:905-916.
172. 3 receptor in various orexigenic pathways. Eur. J. Pharmacol. 2008, 579:229-232.
173. 3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13866-13871.
174. 3 receptor knockout mice following dehydration or angiotensin-II challenge. Pharmacol. Biochem. Behav. 2006, 84:504-510.
175. Yu J., Lou G.D., Yue J.X., Tang Y.Y., Hou W.W., Shou W.T., Ohtsu H., Zhang S.H., Chen Z. Effects of histamine on spontaneous neuropathic pain induced by peripheral axotomy. Neurosci. Bull. 2013, 29:261-269.
176. 6 receptor antibodies. Naunyn. Schmiedebergs Arch. Pharmacol. 2013, 386:885-891.
177. 1 receptor and recollection-based discrimination in a temporal order memory task in the mouse. Pharmacol. Biochem. Behav. 2013, 111:58-63.
178. 1-receptor mediates the motivational effects of novelty. Eur. J. Neurosci. 2008, 27:1461-1474.